A Randomized, Open-Label, Multicenter, Phase III Study of Epoetin Alfa Versus Best Standard of Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

An open-label, noninferiority study to evaluate the impact of epoetin alfa (EPO) on tumor outcomes when used to treat anemia in patients receiving chemotherapy for metastatic breast cancer. Women with hemoglobin ≤ 11.0 g/dL, receiving first- or second-line chemotherapy for metastatic breast cancer,...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical oncology 2016-04, Vol.34 (11), p.1197-1207
Hauptverfasser:	Leyland-Jones, Brian, Bondarenko, Igor, Nemsadze, Gia, Smirnov, Vitaliy, Litvin, Iryna, Kokhreidze, Irakli, Abshilava, Lia, Janjalia, Mikheil, Li, Rubi, Lakshmaiah, Kuntegowda C, Samkharadze, Beka, Tarasova, Oksana, Mohapatra, Ranjan Kumar, Sparyk, Yaroslav, Polenkov, Sergey, Vladimirov, Vladimir, Xiu, Liang, Zhu, Eugene, Kimelblatt, Bruce, Deprince, Kris, Safonov, Ilya, Bowers, Peter, Vercammen, Els
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Anemia - chemically induced Anemia - drug therapy Anemia - prevention & control Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Breast Neoplasms - drug therapy Breast Neoplasms - mortality Breast Neoplasms - pathology Disease Progression Drug Administration Schedule Epoetin Alfa - therapeutic use Female Hematinics - therapeutic use Humans Kaplan-Meier Estimate Middle Aged Odds Ratio Quality of Life Standard of Care Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!